• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有反复胸部感染的VI型黏多糖贮积症

Mucopolysaccharidosis Type VI with Recurrent Chest Infection.

作者信息

Numan Ashraf, Alruwaili Anoud N, Ali Rehab, Alsharari Hamasat, Alanazi Mishal, Alazmi Nouf N, Alsaati Ahmed A

机构信息

Paediatrics, Alqurayyat General Hospital, Alqurayyat, SAU.

Medicine and Surgery, Al Jouf University, Sakaka, SAU.

出版信息

Cureus. 2023 Feb 20;15(2):e35229. doi: 10.7759/cureus.35229. eCollection 2023 Feb.

DOI:10.7759/cureus.35229
PMID:36968901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10032617/
Abstract

Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) is a progressive multi-systemic autosomal recessive disease resulting from a deficiency of arylsulfatase B (N-acetylgalactosamine-4-sulfatase). Here we report the case of a three-year-old male child born full-term via normal vaginal delivery. He had frequent admissions due to a chest infection that started at two months of age. At the age of 23 months, he was admitted after complaining of shortness of breath (SOB) due to asthma and aspiration pneumonia; additionally, dysmorphic features were noticed (single palmar crease, short round toes, coarse facial features such as a flat nose, big lips). A genetic study showed mucopolysaccharidosis VI (MPS VI). At three years of age, he was complaining of cough and SOB. Examination showed wheezing all over the chest, normal first and second heart sounds (S1 and S2), a murmur with no clicks, hepatosplenomegaly, and a palpable left kidney. However, the central nervous system (CNS) and eye examinations were normal. Echocardiography revealed a thickened bicuspid aortic valve, mild aortic regurgitation, and mitral regurgitation. Therefore, the patient presented with different clinical symptoms of MPS VI. It is important to increase the physicians' awareness about MPS by focusing on increasing the probability of MPS as a differential diagnosis whenever patients present with abnormal appearance, limb deformities, and recurrent unexplained infections; hence, making early diagnosis and treatment decisions, leading to a slowing down of the progression of the disease and enhancing the patient's quality of life.

摘要

VI型黏多糖贮积症(马罗-拉米综合征)是一种进行性多系统常染色体隐性疾病,由芳基硫酸酯酶B(N-乙酰半乳糖胺-4-硫酸酯酶)缺乏引起。在此,我们报告一例通过正常阴道分娩足月出生的3岁男童病例。他自2个月大时起就因胸部感染频繁住院。23个月大时,他因哮喘和吸入性肺炎出现呼吸急促而入院;此外,还发现了畸形特征(单一掌纹、短圆脚趾、面部特征粗糙,如扁平鼻、厚嘴唇)。基因研究显示为VI型黏多糖贮积症(MPS VI)。3岁时,他诉说咳嗽和呼吸急促。检查发现全胸有哮鸣音,第一和第二心音(S1和S2)正常,有杂音但无喀喇音,肝脾肿大,左肾可触及。然而,中枢神经系统(CNS)和眼部检查正常。超声心动图显示二尖瓣增厚、轻度主动脉瓣反流和二尖瓣反流。因此,该患者表现出MPS VI的不同临床症状。重要的是,当患者出现外观异常、肢体畸形和不明原因的反复感染时,应通过提高将MPS作为鉴别诊断的可能性来提高医生对MPS的认识;从而做出早期诊断和治疗决策,减缓疾病进展,提高患者生活质量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190c/10032617/2cc829423b84/cureus-0015-00000035229-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190c/10032617/78969a27ef49/cureus-0015-00000035229-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190c/10032617/2cc829423b84/cureus-0015-00000035229-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190c/10032617/78969a27ef49/cureus-0015-00000035229-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/190c/10032617/2cc829423b84/cureus-0015-00000035229-i02.jpg

相似文献

1
Mucopolysaccharidosis Type VI with Recurrent Chest Infection.伴有反复胸部感染的VI型黏多糖贮积症
Cureus. 2023 Feb 20;15(2):e35229. doi: 10.7759/cureus.35229. eCollection 2023 Feb.
2
Mucopolysaccharidosis type VI: case report with first neonatal presentation with ascites fetalis and rapidly progressive cardiac manifestation.黏多糖贮积症 VI 型:一例以胎儿腹水和快速进展性心脏表现为首发表现的新生儿病例报告。
BMC Med Genet. 2020 Feb 19;21(1):37. doi: 10.1186/s12881-020-0972-y.
3
Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a case report.十五年的黏多糖贮积症 VI 型(马罗托-劳米综合征)酶替代治疗:一例报告。
J Med Case Rep. 2022 Jan 25;16(1):46. doi: 10.1186/s13256-021-03240-3.
4
[Analysis of clinical features and arylsulfatase B gene mutation in thirteen Chinese children with mucopolysaccharidosis type VI].[13例中国黏多糖贮积症Ⅵ型患儿临床特征及芳基硫酸酯酶B基因突变分析]
Zhonghua Er Ke Za Zhi. 2014 Jun;52(6):403-8.
5
Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.酶替代疗法可减缓两名日本黏多糖贮积症 VI 型患者的疾病进展。
Mol Genet Metab. 2011 Dec;104(4):597-602. doi: 10.1016/j.ymgme.2011.08.029. Epub 2011 Aug 28.
6
Compound heterozygous missense mutations in a Chinese mucopolysaccharidosis type VI patient: a case report.中国黏多糖贮积症 VI 型患者复合杂合错义突变:病例报告。
BMC Ophthalmol. 2021 May 13;21(1):214. doi: 10.1186/s12886-021-01979-3.
7
Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB.加硫酶:芳基硫酸酯酶B、BM 102、重组人芳基硫酸酯酶B、重组人N-乙酰半乳糖胺-4-硫酸酯酶、重组人芳基硫酸酯酶B
Drugs R D. 2005;6(5):312-5. doi: 10.2165/00126839-200506050-00008.
8
Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up.酶替代疗法延缓了两名日本黏多糖贮积症VI型患者的疾病进展:10年随访
Mol Genet Metab Rep. 2017 Sep 14;13:69-75. doi: 10.1016/j.ymgmr.2017.08.007. eCollection 2017 Dec.
9
Identification of arylsulfatase B gene mutations and clinical presentations of Iranian patients with Mucopolysaccharidosis VI.鉴定伊朗黏多糖贮积症 VI 型患者的芳基硫酸酯酶 B 基因突变与临床表现。
Gene. 2019 Jul 20;706:1-5. doi: 10.1016/j.gene.2019.04.050. Epub 2019 Apr 19.
10
Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.黏多糖贮积症VI型(MPS VI,马罗托-拉米综合征)的自然病史及加硫酶治疗——曾参与MPS VI调查研究患者的10年随访
Am J Med Genet A. 2014 Aug;164A(8):1953-64. doi: 10.1002/ajmg.a.36584. Epub 2014 Apr 24.

本文引用的文献

1
Mucopolysaccharidosis Type VI, an Updated Overview of the Disease.黏多糖贮积症 VI 型:疾病的最新概述。
Int J Mol Sci. 2021 Dec 15;22(24):13456. doi: 10.3390/ijms222413456.
2
Epidemiology of Mucopolysaccharidoses Update.黏多糖贮积症流行病学最新进展
Diagnostics (Basel). 2021 Feb 10;11(2):273. doi: 10.3390/diagnostics11020273.
3
Home treatment of type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome) an alternative at this time of COVID-19 pandemic: A case in Peru.VI型黏多糖贮积症(马罗-拉米综合征)的居家治疗:在2019冠状病毒病大流行期间的一种选择——秘鲁的一个病例
Clin Case Rep. 2020 Oct 31;8(12):3483-3488. doi: 10.1002/ccr3.3420. eCollection 2020 Dec.
4
A case study of three patients with mucopolysaccharidoses in Hue Central Hospital.顺化中心医院三例黏多糖贮积症患者的病例研究。
SAGE Open Med Case Rep. 2020 Jun 29;8:2050313X20938245. doi: 10.1177/2050313X20938245. eCollection 2020.
5
Mucopolysaccharidosis type VI: case report with first neonatal presentation with ascites fetalis and rapidly progressive cardiac manifestation.黏多糖贮积症 VI 型:一例以胎儿腹水和快速进展性心脏表现为首发表现的新生儿病例报告。
BMC Med Genet. 2020 Feb 19;21(1):37. doi: 10.1186/s12881-020-0972-y.
6
Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.MPS IVA 管理建议:基于系统证据和共识的指南。
Orphanet J Rare Dis. 2019 Jun 13;14(1):137. doi: 10.1186/s13023-019-1074-9.
7
Diagnosis of Mucopolysaccharidosis Based on History and Clinical Features: Evidence from the Bajio Region of Mexico.基于病史和临床特征的黏多糖贮积症诊断:来自墨西哥巴希奥地区的证据。
Cureus. 2018 Nov 20;10(11):e3617. doi: 10.7759/cureus.3617.
8
Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment.黏多糖贮积症 VI 型:病理生理学、诊断与治疗。
Front Biosci (Landmark Ed). 2017 Jan 1;22(3):385-406. doi: 10.2741/4490.
9
Diagnostic and treatment strategies in mucopolysaccharidosis VI.黏多糖贮积症VI型的诊断与治疗策略
Appl Clin Genet. 2015 Oct 30;8:245-55. doi: 10.2147/TACG.S68650. eCollection 2015.
10
Identifying the need for a multidisciplinary approach for early recognition of mucopolysaccharidosis VI (MPS VI).确定采用多学科方法早期识别黏多糖贮积症VI型(MPS VI)的必要性。
Mol Genet Metab. 2015 May;115(1):41-7. doi: 10.1016/j.ymgme.2015.03.005. Epub 2015 Mar 26.